Myasthenia gravis (MG) is the most common disorder of the neuromuscular junction. It is the
prototypic autoimmune disease most commonly caused by antibodies to the acetylcholine …

Myasthenia gravis (MG) is the archetypic disorder of both the neuromuscular junction and
autoantibody-mediated disease. In most patients, IgG1-dominant antibodies to acetylcholine …

Background Chimeric antigen receptor (CAR) T cells are highly effective in treating
haematological malignancies, but associated toxicities and the need for lymphodepletion …

Juvenile Myasthenia Gravis (JMG) is a rare disorder, defined as myasthenia gravis in
children younger than 18 years of age. While clinical phenotypes are similar to adults, there …

Introduction Our aim in this study was to identify the prevalence and clinical characteristics of
LRP4/agrin‐antibody–positive double‐seronegative myasthenia gravis (DNMG). Methods …

Background and Objectives Autoantibodies targeting the acetylcholine receptor (AChR),
found in patients with myasthenia gravis (MG), mediate pathology through 3 mechanisms …

Myasthenia gravis (MG) is a B cell–mediated autoimmune disorder of neuromuscular
transmission. Pathogenic autoantibodies to muscle-specific tyrosine kinase (MuSK) can be …

Nicotinic acetylcholine receptors (nAChRs) are widely expressed in many and diverse cell
types, participating in various functions of cells, tissues and systems. In this review, we focus …

Diagnosis and Management of Myasthenia Gravis : CONTINUUM: Lifelong Learning in
Neurology Account Register Activate Subscription Help Subscribe American Academy of …

Objective Patients with myasthenia gravis without acetylcholine receptor (AChR) or muscle-
specific kinase (MuSK) antibodies detected by radioimmunoprecipitation assays (RIAs) are …